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Abstract  
 Background: Thalassemia is the most common autosomal 
abnormality in Syria. Its complications have an important effect on education; 
time off school; sport; difference from friends/ siblings; social interactions; 
and stigmatization. Knowledge of factors associated with quality of life in 
thalassemia patients is necessary for forming appropriate clinical programs, 
social support, and improving treatment outcomes. Purpose: The study was 
to assess the effects of Patients' and Care-givers' Knowledge, Attitude, & 
Practice (KAP) with Quality of Life among Thalassemia Major Patients' in 
Syria. Methods: Cross-sectional descriptive analytical design was conducted 
at the national thalassemia center in Damascus. WHOQOL-BREF and a 
questionnaire developed by the researcher were used to measure the 
participants’ knowledge, attitudes and practices of thalassemia. Results: Total 
of 238 thalassemia patients participated in the study. A statistical significance 
was found regarding improvement of skill and knowledge scores among 
caregivers and thalassemia patients before and after receiving the teaching 
guide from 12.52±1.77 to 14.07±1.01, t=11.447, p=0.000 and from 
34.12±4.50 to 37.43±4.61, t=-8.58, p= .000 respectively. Stigmatization was 
significantly noticed among families caring for thalassemic patients. There 
were a significant differences in the mean score regarding nutritional status 
before and after teaching guide paired t test= 12.11, p= 0.000. A statistical 
significance was found in females regarding social domain p=0.04. However, 
mean scores for overall quality of life were better in females rather than males, 
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but these mean scores were statistically insignificant p>0.05. A statistical 
significant difference in ferritin levels and patient’s age was found. Results 
also revealed that no statistical significant differences was observed between 
overall quality of life of the four domains in relation to the two treatment 
groups (subcutaneous vs oral) and age groups. Conclusion: Thalassemia is a 
socio-economic problem. The most efficient way to reduce risks of having 
affected patients is by increasing the knowledge through training of parents 
regarding the disease. Our findings highlighted that there was lack in patients’ 
knowledge and skills regarding the disease, but a remarkable improvement in 
both knowledge and performance was found after patients received the 
teaching guide, which lead to an increase in overall patient's quality of life.  
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Introduction 
 The term Thalassemia was first used by Wipple and Bradford in 1932, 
derived from Greek word “thlassa” meaning sea and “haemia” meaning 
blood. (Nagaraj, Umashree et al. 2011). Thalassemia is one of the most 
common genetic blood disorders in the world, the most severe form is beta-
thalassemia major, which warrants regular blood transfusions at an early age, 
if it not treated, the result can be early death (El Dakhakhny, Hesham et al. 
2011, Safizadeh and Farahmandinia 2012, Elalfy, Farid et al. 2014). As other 
countries of the Mediterranean region , thalassemia is the most common 
autosomal disorders of the Syrian people, the number of the total registered 
thalassemia patients was 8300 in year 2013 and increasing by almost 800 each 
year, the average carrier rate is 5–7% of the total population  (Al-Zir 2009, 
Touma, AlKeba et al. 2013). Regular blood transfusions and iron chelation 
therapy (ICT) have significantly improved survival, reduced morbidity and 
enhanced health related quality of life (HRQoL) of patients with beta-
thalassemia major (BTM) (Touma, AlKeba et al. 2013, Hatami and Motamed 
2014). 
 There has been very limited researches about the effects of thalassemia 
on QoL especially for pediatric patients (Hatami and Motamed 2014). No 
studies have been done to measure or to assess awareness of the Syrian people 
or families with thalassemic patients regarding knowledge, attitude and 
practices related to quality of life for these patients in Syria. As such more 
attention is needed in issues related to knowledge and understanding of the 
illness, lifelong compliance and adherence to chronic treatment regime and 
attitudes of patients and family members as well as quality of interpersonal 
relationships (Jantan, Muhammad et al. 2011).  
 The most effective way to decrease complications of thalassemia 
patients is by increasing knowledge, attitude and practice awareness of these 
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patients and their parents about the disease and its management, which will 
result in a positive impact in their quality of life. This will improve their 
performance to deal with their lifelong disease and its challenges during the 
period of management (Kourorian Z et al 2014 (Dehkordi and Heydarnejad 
2008). The obvious role of parents’ education in the prevention of beta-
thalassemia is evident in the study of Dehkordi and Heydarnejad 2008 which 
indicated that population with poor pre marriage knowledge of the couples 
about the disease resulted in 62.5% of the affected children. This problem 
could have been reduced by improvement of the parents’ health education 
(Dehkordi and Heydarnejad 2008). 
 In Syria, only one thalassemia organization is found in the capital 
Damascus that provides the social support and information for the patients and 
their family. Currently the Syrian Ministry of Health (SMOH) has started with 
a training program for health personnel to provide good quality care and 
counselling for the patients and families (Touma, AlKeba et al. 2013). 
Unfortunately, till now there are no professional psychologists who are 
working in institutions caring for thalassemia to support and follow up the 
cases.  
 Patients with β-thalassemia major require iron-chelation therapy to 
avoid the complications of iron overload such as severe anemia with an 
enlarged spleen, pallor, irritability, growth retardation, delayed puberty, 
abdominal swelling, and jaundice (Muncie Jr and Campbell 2009, Milat, 
Wong et al. 2012). Other severe complications such as heart failure, cardiac 
arrhythmia, liver disease, endocrine complications and infections are common 
among patients with β-thalassemia and may impact negatively on patients’ 
quality of life (QOL) (Borgna-Pignatti and Gamberini 2011, Liem, Gilgour et 
al. 2011, Pennell, Carpenter et al. 2011, Ali, Tarawah et al. 2015).   
 Effective treatment of patients with β-thalassemia major consists of 
regular blood transfusions, intensive administration of iron-chelating agents 
such as deferoxamine (DFO) by subcutaneous infusions, or deferiprone (DFP) 
and deferasirox (DFX) that are taken orally, Spleenectomy and Bone marrow 
transplantation (Schrier and Angelucci 2005, Cohen 2006, Capellini, Cohen et 
al. 2008, Cianciulli 2008, Vichinsky, Levine et al. 2008, Murad, Moassas et al. 
2014). Deferoxamine (Desferal), subcutaneously or intravenously, has been 
the treatment of choice (Muncie Jr and Campbell 2009). Chelation therapy has 
two main forms: subcutaneous slow infusion by a portable pump 
(deferoxamine) and oral (deferasirox, deferiprone), whereas  most patients in 
Syria use classical chelation therapy using desferrioxamine and the infusion 
pump (Al-Zir 2009, Trachtenberg, Mednick et al. 2012). The cost of treatment 
per β-thalassemia patient is up to $1500.00 per year (Murad, Moassas et al. 
2014).  
 Serum ferritin is increasing as an indicative of compliance with 
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deferasirox treatment (Milat, Wong et al. 2012). Serum ferritin is the best test 
to screen for iron deficiency anemia (Muncie Jr and Campbell 2009). 
Consequently, compliance with regular administration of chelation agents is a 
key feature to the long-term health of thalassaemic patients (Atkin and Ahmad 
2000):whereas, the serum ferritin level that identifies safe levels of body iron 
with respect to the development of complications of iron overload is < 2500 
mcg/L (Olivieri, Nathan et al. 1994, Muncie Jr and Campbell 2009).  In a study 
done by (Pakbaz, Fischer et al. 2005) to investigate the factors that can 
improve adherence to iron chelation therapy with DFO in patients with 
thalassemia. Ninety patients with thalassemia major were assessed for 
adherence to chelation therapy by using Liver Iron Concentration (LIC) and 
Serum Ferritin (SF). Results showed that patient education and counseling 
about the benefits of chelation therapy can play an important role in improving 
adherence. Frequent measurement of liver iron concentration can be valuable 
in modifying patients' belief about the medication because it can give evidence 
for the effectiveness of DFO in reducing LIC and therefore lead to a better 
compliance. (Pakbaz, Fischer et al. 2005).  
 The magnitude of thalassemia is masked by infections and nutritional 
deficiencies (Nagaraj, Umashree et al. 2011). Therefore, the thalassemia 
patients should avoid food rich in iron and drink a cup of tea with every meal 
because it interferes with iron absorption in the diet patient should also avoid 
food rich of vitamin- C during meals (Wonke 2001, Caro, Ward et al. 2002, 
Capellini, Cohen et al. 2008). 
 The Quality of Life (QoL) of individuals with thalassaemia major is 
influenced by the following factors: impact of the diagnosis and treatment on 
family stability and family dynamics, having a chronic condition manifisting 
by bone deformities, short stature, leading to poor self-image; treatment 
measures like frequent hospital visits for transfusion; nightly subcutaneous 
infusions; delayed or absent sexual development and impaired fertility; 
complications of the disease and therapeutic interventions such as heart 
disease, bone disease, diabetes, infections; and uncertainties about the future, 
difficulties in long-term planning (Telfer, Constantinidou et al. 2005, 
Shaligram, Girimaji et al. 2007, Jafari, Lahsaeizadeh et al. 2008, Scalone, 
Mantovani et al. 2008). Hence, the impact of iron chelation therapy (ICT) on 
Quality of Life (QoL) will not be noticed until major complications begin to 
occur in the teens or early twenties for patients with thalassaemia (Abetz, 
Baladi et al. 2006, Ansari, Baghersalimi et al. 2014). The aim of this study was 
to assess the effects of patients' and care-givers' knowledge, attitude, & 
practice (KAP) on quality of life among β-thalassemia major patients in Syria, 
and according to the research results, we are looking to develop a teaching 
guide based on the previous assessment of home caregivers and patients 
regarding to their needs. 
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Methods and design 
Sample and setting 
 A cross-sectional descriptive analytical study was performed from 20 
September 2016 to 22 December 2016, a total of 238 thalassemia patients and 
their caregivers who visited the national thalassemia center in Damascus were 
included in this study. The center was established in 1997 with over 1200 
thalassemia patients. The diagnosis of thalassemia major is confirmed using 
compete blood count and hemoglobin electrophoresis in the center. The center 
provides blood transfusions, desferrioxamine and social support (Gharaibeh, 
Amarneh et al. 2009). This site was selected for the purpose of this study, 
because it is considered the main center that provides a holistic care for 
thalassemia patients' children/ adolescents or adults in Syria.  
 The inclusion criteria were, A: (1) All the subjects to be diagnosed as 
beta-thalassemia major and confirmed in medical record by physician, (2) 
Those receiving blood transfusion every 3-4 weeks (3) Those taking iron 
chelation therapy (Desferal medication subcutaneously by using infusion 
pump at home (4) All patients have to be within the three age categories I) 
aged 5- to less than 12 years, II) aged 12-19 years, and III) aged =>19 years. 
B: All caregivers of patients at home (next of kin) were included, one for each 
patient. An official letter issued from University of Gezira and Ministry of 
Health in Syria to obtain approval agreement to conduct the study, a 
permission to use WHOQOL-BREF was taken, also a written consent was 
obtained from each patient. Home caregivers and patients were assured that 
there were no harms, risks and discomfort caused to them through 
participation. The teaching guide was distributed to the patients or caregivers 
through a period of data collection for initial assessment. Every patient and 
caregiver was interviewed for an average of one hour to fill the data collection 
formats directed towards each. All interviews were done with a patient or 
home caregiver accompanying the child who was attending the center 
according to his/her appointment for receiving blood transfusion and treatment 
in the governmental center. The researcher assessed the patients and their 
caregiver's knowledge and skills in the first interview, followed by handing of 
the thalassemia guide. Two months later, a second interview was conducted to 
reassess the participants. 
 
Instrument 
 Five tools were used in the process of data collection.   
1. Validated World Health Organization Quality of Life (WHOQOL-
BREF) questionnaire was used for the purpose of this study. The WHOQOL-
BREF questionnaire covered four domains - physical, psychological, social 
relationships and environment.  
 The researcher designed and developed the following structured 
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questionnaire: 
2. Home caregivers' knowledge about thalassemia major patient 
interview. 
3. Home caregiver attitudes interview sheet. 
4. Physical assessment checklist. 
5. Designed observational checklist was used to observe patients or their 
caregivers at their homes while preparing and administering the Desferal 
subcutaneously. 
 Demographic characteristics, disease features and complications were 
analysed with mean score of QOL using chi-square, ANOVA and t-test where 
appropriate. Statistical significant was considered as P-value < 0.05. The SPSS 
version 20 was used to analyse the data.  
 
Results 
 Table 1- represents the general characteristics of patients in relation to 
birth order, gender, educational level, marital status and age groups. Male 
constituted 53.4%, while 46.6% were female. As regard age group, two thirds 
of the sample were childhood and adolescent (72.3%). 36.6% were in the age 
group of 5 to less than 12 years (20.6% male, and 16.0% female), while  35.7% 
were in the age group 12 to less than 19 years (18.5% male, and 17.2% female. 
Adulthood category for 19 years and above was the lowest about 27.7% 
(14.3% of them male and 13.4 % were female). The majority of patients (71%) 
were in school education.  
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Table 1: General Characteristics of the patients. 
 
*Applicable (Patients' age equal or more 16 years) 
*Not applicable (Patients' age less than 16 years old) 
 
 Table 2 portrays home caregivers' characteristics. Mothers were 
caregivers for patients in about two thirds of the sample (62.6%). Fathers and 
patient himself were considered caregivers in 8.0%, 27.7% of cases 
respectively. The majority of caregivers 75.6% were married. As regard to 
educational level of caregivers, data indicated that 47.1%, 53% of caregivers 
got their school education and higher education respectively. 66.4 % of 
caregivers were un-employed. 
  
 
           Characteristics 
Male Female Total 
No=  127 % No= 111  % No= 238 % 
Patient gender 127 53.4 111 46.6 238 100 
Birth order of thalassemia   
Patient in the family: 
First 
Second 
Third 
Fourth 
Fifth 
Sixth and More 
 
56 
38 
20 
10 
2 
1 
 
 
23.5 
16 
8.4 
4.2 
0.8 
0.4 
 
41 
30 
18 
12 
7 
3 
 
 
17.2 
12.6 
7.6 
5 
2.9 
1.3 
 
97 
68 
38 
22 
9 
4 
 
 
40.8 
28.6 
16 
9.2 
3.8 
1.7 
Educational level: 
KG 
Elementary 
Preparatory 
Secondary 
Diploma 
University 
 
8 
40 
25 
30 
7 
17 
 
3.4 
16.8 
10.5 
12.6 
2.9 
7.1 
 
9 
25 
28 
21 
7 
21 
 
3.8 
10.5 
11.8 
8.8 
2.9 
8.8 
 
17 
65 
53 
51 
14 
38 
 
7.1 
27.3 
22.3 
21.4 
5.9 
16 
 Marital Status: 
Single 
Married 
Not applicable* 
 
52 
8 
67 
 
21.8 
3.4 
28.2 
 
52 
5 
54 
 
21.8 
2.1 
22.7 
 
104 
13 
121 
 
43.7 
5.5 
50.8 
 Age groups: 
Childhood (5- less than 12 years) 
Adolescent (12- less than 19 years) 
Adulthood (19 years & above) 
 
49 
44 
34 
 
20.6 
18.5 
14.3 
 
38 
41 
32 
 
16.0 
17.2 
13.4 
 
87 
85 
66 
 
36.6 
35.7 
27.7 
Mean + SD   15.67 + 7.48 
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Table 2: Home caregivers' characteristics 
 
 Table 3 portrays about two thirds of sample (66.0 %) had insufficient 
monthly income at all while 29.8 % of families had sufficient income. More 
than half of the sample (58.4%) was from rural areas. Also the table depicts 
great proportion of sample (65.5 %) had consanguineous parents. Less than 
half of sample (44.5%) had a positive family history of thalassemia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics 
No 
N = 238 
 
% 
Caregivers: 
Mother 
Father 
Brother / Sister 
Patient himself 
Marital Status 
Single 
Married 
Divorced / Widowed 
Level of Education 
Basic education 
Preparatory 
Secondary 
Diploma  
University 
Occupational status 
Governmental sector employee 
Private sector employee 
Retired 
Un-employed 
Other 
 
 
149 
19 
4 
66 
 
57 
180 
1 
 
9 
23 
80 
67 
59 
 
31 
31 
16 
158 
2 
 
62.6 
8.0 
1.7 
27.7 
 
23.9 
75.6 
0.4 
 
3.8 
9.7 
33.6 
28.2 
24.8 
 
13.0 
13.0 
6.7 
66.4 
0.8 
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Table 3. Percent distribution of socioeconomic status and family history 
Data N= 238 % 
Categorical monthly income 
in Syrian Pound (SP) 
Sufficient 
Sufficient and few saved 
Insufficient at all 
Type of accommodation (before War) 
Own 
Rent  
Type of accommodation (During War) 
Own 
Rent  
Inner Refugee   
Residence 
Urban 
Rural 
 
71 
10 
157 
 
185 
53 
 
79 
72 
87 
 
99 
139 
 
29.8 
4.2 
66.0 
 
77.7 
22.3 
 
33.7 
30.0 
36.3 
 
41.6 
58.4 
Mean Crowding index .6187 + .2814 
Parents' relatives (consanguinity): 
Yes 
No 
Degree of relatives: 
Daughter of cousin/uncle 
Daughter of aunt 
Other 
Anyone affected with thalassaemia 
Within the whole family: 
Yes 
No 
Degree of relative: 
First class 
(Father, mother, brother, sister) 
Second class 
(Grandfather/mother, cousins/aunt, uncle 
Third class 
(Others from the family) 
 
Type of thalassaemia: 
Minor 
Intermediate 
Major 
I don't know 
N= 238 
156 
82 
N= 150 
70 
48 
32 
N= 238 
106 
132 
N= 109 
50 
39 
20 
 
N= 109 
10 
6 
91 
2 
 
65.5 
34.5 
 
46.7 
32.0 
21.3 
 
44.5 
55.5 
 
45.9 
35.8 
18.3 
 
 
9.2 
5.5 
83.5 
1.8 
 
 Table 4 Depicts great proportion of sample (76.9%) had knowledge 
about thalassemia. Nearly third of sample 37.0 % knew the causes of 
thalassemia and 16.6% knew the methods of prevention. Regarding the source 
of information the doctors were the main source for the majority of the sample 
60.0%. 
 
European Scientific Journal April 2018 edition Vol.14, No.12 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 
317 
Table 4: Home caregivers’ knowledge about Thalassemia 
Data No. % 
Knowledge about thalassaemia: 
Yes 
No 
Areas of information: 
Causes 
Prevention 
Signs & symptoms 
Modes of transmission 
Treatment 
Complications 
Sources of information: 
Doctors 
Nurse 
Family 
Books 
Brochures & Newspaper  
N= 238 
183 
55 
N= 185 
67 
30 
31 
19 
32 
2 
N=185 
111 
45 
23 
3 
3 
 
76.9 
23.1 
 
37.0 
16.6 
17.1 
10.5 
17.7 
1.1 
 
60.0 
24.3 
12.4 
1.6 
1.6 
 
 Table 5 shows an improvement of caregivers’ knowledge after 
receiving the teaching guide in blood components & functions, hemoglobin 
level, causes of thalassemia, prevention, treatment and nutrition. There is an 
improvement in the overall caregivers’ knowledge regarding thalassemia, 
whereas the mean and standard deviation was 34.12±4.50 before receiving the 
teaching guide and 37.43±4.61 after receiving the teaching guide. 
Table 5: Mean score caregivers' knowledge about Thalassemia of pre and post teaching 
guide  
Area of knowledge Mean score  
 Before Receiving 
Guide 
After Receiving 
Guide 
Paired t. test P. 
value 
1. Blood components & functions 4.07 5.30 -19.97 .000* 
2. Hemoglobin level 1.80 2.15 -5.65 .000* 
3. Causes of thalassaemia 7.29 8.65 -11.03 .000* 
4. Disease transmission 2.90 2.97 -0.719 0.473 
5. Prevention 3.12 3.49 -6. 12 .000* 
6. Treatment 13.81 13.04 3.77 .000* 
7. Nutrition 1.72 1.11 12.11 .000* 
Overall knowledge 34.12±4.50 37.43±4.61 -8.58    .000* 
* Significant P <0.05 
 
 Table 6 Depicts great proportion of sample (59.2 %) had no difference 
from peers.  Nearly one third of the sample 37.1 % had physical changes such 
as growth retardation, 24.7% had facial changes, 16.5 % had a weakness& 
exercise intolerance, 11.3% had skin color changes and 10.3% had abdominal 
changes and the majority 67.7% were upset from these differences. Regarding 
to social activities, more than half of the sample 55.9% didn’t engage in group 
activities and play. 
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Table 6: Description of Self –Image of Patients with Thalassaemia Major 
    
Table 7 shows (39.9%) of sample had compliance with treatment. 
Great proportion of the sample (61.7 %) had a capability to inject him/herself 
with Desferal by using pump. Regarding reasons for not injecting Desferal 
subcutaneously, third of the sample (32.5%) answered they had a lack of skills, 
(22.5 %) were afraid and (45.0%) had been both lacking of skills and afraid. 
 
 
 
 
           Variables 
Male Female Total 
No=127 % No= 111 % No= 238 % 
Different from peers: 
Yes 
No 
 
52 
75 
 
21.8 
31.5 
 
45 
66 
 
18.9 
27.7 
 
97 
141 
 
40.8 
59.2 
Total No. 52 % No. 45 % No. 97 % 
Different in what: 
Facial changes 
Physical changes as 
growth retardation 
Weakness & exercise 
intolerance 
Skin color changes 
Abdominal enlargement 
 
13 
 
20 
 
10 
 
7 
2 
 
13.4 
 
20.6 
 
10.3 
 
7.2 
2.1 
 
11 
 
16 
 
6 
 
4 
8 
 
11.3 
 
16.5 
 
6.2 
 
4.1 
8.2 
 
24 
 
36 
 
16 
 
11 
10 
 
24.7 
 
37.1 
 
16.5 
 
11.3 
10.3 
Total No. 51 % No. 42 % No. 93 % 
Disturbed from these 
differences: 
Yes 
No 
 
34 
17 
 
36.6 
18.3 
 
29 
13 
 
31.2 
14 
 
63 
30 
 
67.7 
32.3 
Total No.  127 % No. 111 % No.  % 
Have special interest and 
hobbies 
Yes 
No 
 
 
110 
17 
 
 
46.2 
7.1 
 
 
91 
20 
 
 
38.2 
8.4 
 
 
201 
37 
 
 
84.5 
15.5 
Total No.  127 % No. 111 % No.  % 
Engage in group activities 
and play 
Yes 
No 
 
53 
74 
 
22.3 
31.1 
 
52 
59 
 
21.8 
24.8 
 
105 
133 
 
44.1 
55.9 
Reasons for not engaging 
in activities 
 
Shamed face 
Inapproperate physical 
fitness 
Others 
Total 
 
 
12 
32 
29 
73 
 
 
9.2 
24.6 
22.3 
56.2 
 
 
18 
20 
19 
57 
 
 
13.8 
15.4 
16.4 
43.8 
 
 
30 
52 
 
48 
130 
 
 
23.1 
40.0 
36.9 
100 
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Table 7: Shows percent distribution of patients' / caregivers' behaviors regarding Desferal 
injection 
 
Behavior 
 
Male Female Total  
No= 127 % No=111 % No=238 % 
Compliance with treatment 
Yes 
No 
Not Apply** 
Capability to inject him/herself 
with Desferal by using pump 
Yes 
No 
Total 
Reasons for not injecting 
Desferal Subcutaneously: 
 A –lack of skills 
 B – Afraid 
C –Both A & B 
 Total 
 
48 
12 
67 
 
 
40 
20 
60 
 
7 
2 
9 
18 
 
20.2 
5.0 
28.2 
 
 
34.8 
17.4 
52.2 
 
17.5 
5.0 
22.5 
45.5 
 
47 
8 
56 
 
31 
24 
55 
 
6 
7 
9 
22 
 
19.7 
3.4 
23.5 
 
27.0 
20.9 
47.8 
 
15.0 
17.5 
22.5 
55.0 
 
95 
20 
123 
 
71 
44 
115 
 
13 
9 
18 
40 
 
 
39.9 
8.4 
51.7 
 
61.7 
38.3 
100 
 
32.5 
22.5 
45.0 
100 
**Not apply means that patients whose age less than 15 years old do not use Desferal by 
using infusion pump. 
  
  Table 8 Shows descriptive statistics for serum ferritin and hemoglobin levels (3852, 8.25) 
respectively.   
 N Minimum Maximum Mean Std. 
Deviation 
F Sig 
Serum Ferritin 
level 
238 374.0 18575.0 3852.0 2700.35 6.46 .002* 
Hemoglobin 
Level 
238 5.9 11.3 8.255 0.938 0.66 .52 
* Significant P < .05 
 
 Table 9 shows changes in physical structure of thalassemia patients. 
Regarding to changes in physical growth retardation findings show half of 
sample had normal physical growth, while quarter had changes in height and 
weight. About two thirds of sample had normal facial bone, while (40%) had 
different facial bone changes. More than two thirds of sample had normal 
abdomen, while (28%) had an enlargement in the abdomen. 
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Table 9: Changes in Physical Structure of Thalassaemic patients 
Changes in Physical Structure N= 238 % 
Physical growth retardation (wt + ht) 
Height 
Weight 
Height and weight 
Normal 
Facial Bone changes 
Protrusion of the lip and upper central incisors. 
Prominent frontal and parietal bones 
Flat or depressed bridge of the nose 
Enlarged maxilla 
Normal 
Abdominal enlargement 
Enlarged  
Normal 
 
35 
24 
58 
121 
 
 
39 
26 
12 
19 
142 
 
 
67 
171 
 
14.7 
10.1 
24.4 
50.8 
 
 
16.4 
10.9 
5.0 
8.0 
59.7 
 
 
28.2 
71.8 
 
 The results show there was an improvement in all steps of this 
procedure and there was a statistical significant in overall caregivers’ and 
patients’ regarding this skill, whereas the mean and standard deviation was 
12.52±1.77 before receiving the teaching guide and 14.07±1.01 after receiving 
the teaching guide (table 10). 
Table 10: Distribution of caregivers or thalassemic patients according to steps of 
administering Desferal Sc. By using infusion pump 
Steps for administering Desferal SC Before Guide  
n=115 
After Guide  
n =115 
No % Yes % No % Yes % 
1. Prepare the equipments 5.2 94.8 0.0 100.0 
2. Put some pain-killer cream on the skin before the 
injection. 
93.9 6.1 79.1 20.9 
3. Clean and dry hands before the injection. 33.9 66.1 10.4 89.6 
4. Sterilize and clean the injection bottle with alcoholic 
swab. 
53.0 47.0 16.5 83.5 
5. Calculate the Desferal dosage according to the 
doctor prescription. 
3.5 96.5 1.7 98.3 
6. For every bottle, inject 4-5 c.c. injection water. 4.3 95.7 1.7 98.3 
7. Withdraw Desferal as prescribed with a syringe 
10cm. 
7.8 92.2 7.8 92.2 
8. Connect the intravenous catheter to syringe and 
fixed it to pump. 
0.0 100.0 0.0 100.0 
9. Select appropriate injection site 4.3 95.7 0.9 99.1 
10. The needle should go all the way beneath the skin 
with 45 angles. 
27.0 73.0 12.2 87.8 
11. Fix the position of the intravenous catheter with 
adhesive tape 
8.7 91.3 5.2 94.8 
12. Injection speed = length of Desferal occupying the 24.3 75.7 9.6 90.4 
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syringe / injection time. 
13. Be sure the pump is working by pressing on the 
button of operation. 
3.5 96.5 2.6 97.4 
14. Observe injection site & stop the infusion bump 
when medicine finished. 
8.7 91.3 6.1 93.9 
15. Clean and replace all equipments after the 
injection. 
33 67 13 87 
16. Clean and dry hands after the injection. 38.3 61.7 25.2 74.8 
Mean ±SD 12.52±1.77 14.07±1.01 
t-test (p value) 11.447 (0.000)* 
*Significant at level p<=0.05 
 
 The findings show there were differences between adolescents and 
adults regarding to the four domains of quality of life, and it was higher in 
adults than adolescents but without significant relationship (table 11).  
Table 11: Relationship between quality of life domains and patients age group 
Patient Profile Quality of life Domains 
Physical 
Health 
Psychological Social 
relationship 
Environmental Overall 
QoL 
Patient 
age 
group 
n=158 
12-
≥19 
n=88 
62.4±16.3 59.8±19.6 65.5±26.3 61.5±19.7 62.3±18.0 
19- 
n= 70 
67.2±18.0 63.8±20.1 72.4±21.3 66.6±16.6 67.5±16.4 
t- test (p value) 1.72 
(0.083) 
0.932 
(0.204) 
1.94 
(0.077) 
1.19 
(0.088) 
1.89 
(0.060) 
*Significant at level p<=0.05 
  
The findings show there were differences between males and females 
regarding to the four domains of quality of life, and it were higher in males 
than females in psychological and environmental domains, while it was 
statistically significant in social relations in females than males (71.2±22.2 
compaed with 66.1±26.2) (p=0.04), the overall quality of life was higher in 
females than males but without statistically significant (table 12).  
Table 12: Relationship between quality of life domains and the patient gender 
Patient profile Quality of Life Domains 
Physical 
Health 
Psychological Social 
Relationships 
Environmental Overall 
Quality of 
Life 
gender 
n=158 
Male 
n=82 
64.1±18.4 62.1±20.7 66.1±26.2 64.2±20.0 64.2±18.8 
Female  
n=76 
65.0± 15.8 61.0±19.5 71.2±22.2 63.2±16.9 65.1±15.9 
t-test 
(p value) 
0.358 
(0.61) 
0.322 
(0.585) 
1.334 
0.04* 
0.330 
(0.089) 
0.033 
(0.737) 
*Significant at level p<=0.05 
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 The findings show there were differences between the four domains of 
quality of life regarding two types of treatment (subcutaneous and oral), 
subcutaneous treatment was higher in all domains, the overall quality of life 
was higher also in subcutaneous but not statistically significant (table 13).  
Table 13: Relationship between quality of life domains and the type of treatment 
Patient profile Quality of Life Domains 
Physical 
Health 
Psychological Social 
Relationships 
Environmental Overall 
Quality 
of Life 
Type of 
treatment 
n=158 
Subcutaneous 
n=115 
65.7±18.2 62.6±21.3 68.9±23.8 64.7±18.8 65.2±17.6 
Oral  
n=43 
61.0± 
14.3 
59.5±16.7 65.6±23.8 62.1±18.3 62.1±16.0 
t-test (p value) 
(p value) 
1.59 
(0.062) 
0.073 
(0.090) 
0.683 
(0.645) 
1.06 
(0.289) 
1.147 
(0.233) 
*Significant at level p<=0.05 
 
Table 14: Relationship of Quality of Life Level with Overall Knowledge, Performance and 
Attitude of Caregiver 
Caregiver knowledge, Performance and Attitude (KAP) Quality of Life Level 
Unsatisfactory 
QoL 
Satisfactory QoL 
Overall knowledge Before guide 
   n= 238 
32.72±3.34 34.96±4.25 
t-test (p value) 1.77 (0.059) 
Overall knowledge After guide 
   n= 238 
32.72±6.51 35.86±4.76 
t-test (p value) 2.53 (0.023)* 
Overall Performance Before guide   n= 115 9.83±1.58 12.90±1.36 
t-test (p value) 8.062 (0.169) 
Overall Performance After guide 
   n= 115 
14.00±1.41 14.07±1.01 
t-test (p value) 0.109 (0.642) 
Overall Attitude 62.45±8.75 60.58±9.73 
t-test (p value)   n=158 2.562 (0.252) 
*Significant at level p<=0.05 
 
Discussion 
 Beta-thalassemia major affects males and females equally and no sex 
difference was reported (Muncie Jr and Campbell 2009, Perisano, Marzetti et 
al. 2012). Findings of this study show a statistical significant was found in 
females regarding to social domain (p=0.04). However, mean scores for 
overall quality of life were better in females rather than males, but these mean 
scores were statistically insignificant (p>0.05). These findings were consistent 
with those of Dahlui and colleagues (Dahlui, Hishamshah et al. 2009) and 
(Gharaibeh and Gharaibeh 2012) regarding gender, male and female children 
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reported similar mean score for quality of life. Furthermore, the findings 
showed that patient’s gender was not associated with HRQoL scores. These 
findings were inconsistent with those reported by Seyedifar et al  (Seyedifar, 
Dorkoosh et al. 2016) and Ansari et al (Ansari, Baghersalimi et al. 2014) who 
found that there were significant differences in quality of life according to 
gender, female patients had better quality of life than males significantly 
(p=0.05). 
 Regarding socio-economic status, results show two thirds of families 
said their monthly income was insufficient at all time. This finding was 
congruent with other studies that reported nearly half of the thalassemia 
families had employment and financial problems as a result of thalassemia, 
presenting thalassemia as a socio-economic problem (Zani, Di Palma et al. 
1995, Aydinok, Erermis et al. 2005, Khurana, Katyal et al. 2006, Gharaibeh 
and Mater 2009, Ayoub, Radi et al. 2013). A further study carried out by 
Prasomsuk et al. reported that mothers caring for children with thalassemia 
major in Thailand had financial difficulty due to loss of income and increased 
expenses related to treatment, transportation and living costs during their 
children's admission to the hospital was the main cause of financial burden for 
these mothers. Not surprisingly, the burden became greater when the children 
became sick (Prasomsuk, Jetsrisuparp et al. 2007).  
 In our study, parents are consanguineous in 65.5% of patients' families. 
Consanguineous marriage is a social phenomenon among Syrians, it is higher 
in urban than rural areas 30.3% and 39.8% respectively (Othman and Saadat 
2009). In the present study, 23.1% of the sample had knowledge deficit 
regarding causes, prevention, signs and symptoms, transmission, treatment 
and complications of thalassemia. Many other studies (Mrayyan, Al-Omary et 
al. , Hanl, Han et al. 1992, Seyam and Assemi 2010, Miri‐Moghaddam, Zadeh‐
Vakili et al. 2011, Shrivastava, Sinha et al. 2011, Al Hajeri and Al Arrayed 
2012, Ishaq, Hasnain Abid et al. 2012, Kourorian, Azarkeivan et al. 2014) 
reported there was a lack of information and knowledge through the 
thalassemia patients and families regarding the signs and symptoms, causes 
and treatment of this disorder.  
 Health professionals are facing many problems in giving care to 
thalassemia patients. The main problem is parents’ lack of awareness about the 
disease. Medical staff can help to increase knowledge of families’ having 
patients with thalassemia disorder (Dehkordi and Heydarnejad 2008, Patricia 
Ault 2009).  In this study, caregivers’ overall knowledge score ranged from 16 
– 45 out of 50 regarding thalassemia major and its management before 
teaching guide with a mean score M±SD (34.12±4.50), while after teaching 
guide ranged from 21-47 with a mean score M±SD (37.43±4.61). Overall, this 
study found a statistical significant relationship among caregivers and 
thalassemia patients in six out of seven areas of knowledge that where assessed 
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before and after distributing the teaching guide. Results of this study are 
parallel with other studies (Romeo, Di Gregorio et al. 1997, Yang, Chen et al. 
2001, Heydarnejad and Hasanpour-Dehkordi 2008, Wong, George et al. 2011) 
that found the education of parents regarding thalassemia could have 
significant positive effect on increasing their knowledge. 
 As results revealed in our study, there were significant differences in 
the mean scores regarding nutritional status before and after teaching guide 
(paired t test= 12.49, p= 0.000). This could be explained that nutritional 
information included in the guide had an influence on their knowledge score 
that will reflect on nutritional behavior of thalassemia patients later on during 
their daily life. 
 Findings of this present study show no significant difference among 
three independent groups of caregivers regarding overall attitude score of four 
categories included in the questionnaire (F ratio = 0.926; P= 0.398). Through 
examining of each attitude-item separately, one item (q25) was statistically 
significant among the independent groups (F ratio =3.216, p= 0.042). This 
item “question 25: the family would not like others to know their affected 
children particularly if the family has a history for thalassemia”. These 
findings are agreement with other studies (Zahed and BOU‐DAMES 1997, 
Alkuraya and Kilani 2001, Zahed, Nabulsi et al. 2002, Kourorian, Azarkeivan 
et al. 2014, Basu 2015) who found that the majority of their study sample has 
a positive attitude regarding thalassemia. 
 In Syria Al-Zir 2009 reported that carriers may decide to undergo 
genetic testing and counseling to assess potential risks to their children, 
including prenatal testing, so we have given emphasis to health education. We 
believe that these measures will improve the quality of our life (Al-Zir 2009). 
Also in Syria, Murad 2014 reported in his study conducted among Syrian 
families to evaluate the prenatal diagnosis (PND) of β-thalassemia and sickle 
cell anemia results pointing to a successful future for PND of β-thalassemia 
and sickle cell anemia in Syria, using a rapid and accurate molecular method 
(Murad, Moassas et al. 2014). Also in Syria Kyriacou 2000 mentioned that 
their findings provide a sound foundation on which to base a preventive 
program for thalassemia and we believe that the data that we present will 
facilitate the improvement of medical services such as carrier screening, 
genetic counseling, and prenatal diagnosis. Furthermore a detailed knowledge 
of the molecular pathology of β-thalassemia will strongly improve the prenatal 
diagnosis services in Syria (Kyriacou, Quobaili et al. 2000).  
 Thalassemia was commonly seen by the community as a stigma for the 
patients and their families, who were often isolated (Bush, Mandel et al. 1998). 
This led most parents to be very secretive about the illness, and to avoid 
discussion of the subject with friends and relatives. The ill children were 
literally hidden away, did not attend school, and were not allowed to play with 
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other children (Bush, Mandel et al. 1998, Caocci, Efficace et al. 2012). In this 
present study, stigmatization was significantly noticed among families caring 
for thalassemia patients. This result was congruent with Gharaibeh et al 
(Gharaibeh, Amarneh et al. 2009) and (Wong, George et al. 2011) who found 
that stigmatization had many risks on thalassemia patients such as decreasing 
the opportunity for social interactions with increasing the chance for isolation 
and its negative impact in increasing the psychological burden, especially on 
adolescent patients aged (13-18) years old. 
 Old children and adolescents with thalassemia major have difficulty to 
develop positive body image. Caregivers reported that (40.8%) of their 
children were different from peers. Such feeling is reported by many authors 
(Angastiniotis and Hadjiminas 1981, Politis 1998, Angastiniotis 2002, 
Aydinok, Erermis et al. 2005, Abetz, Baladi et al. 2006, Cao and Kan 2013). 
Differences in their appearance as facial aspect, growth retardation and skin 
color made them the subject of sidelong looks and curiosity (Massaglia, 
Pozzan et al. 1986, Nagaraj, Umashree et al. 2011) . In the present study, the 
common causes of such feeling were physical changes as growth retardation, 
facial changes, weakness and exercise intolerance, skin color and abdominal 
enlargement. Therefore, this study revealed that (67.7%) of children and 
young adults were disturbed from these differences as reported by caregivers. 
The vast majority of thalassemia patients told their parents about negative 
feelings coming from others. The findings of this study were similar to Abetz 
et al. who reported that the impact of iron chelation therapy on patients with 
thalassemia is high (Abetz, Baladi et al. 2006, Payne, Rofail et al. 2008), and 
with Beratis 1993 who found that thalassemia patients demonstrated a 
significantly greater frequency of disturbed behavior towards relatives and 
friends than the control subjects (Beratis 1993). 
 The results of this study showed that vast majority of patients attach 
much importance to their appearance. It was also found that (84.5%) of 
thalassemia patients have special interests and hobbies, but unfortunately 
(55.9%) of the patients did not engage in group activities and play. This is 
because of exercise intolerance and feeling of shamed face as mentioned by 
them. Practicing sport was one of the burdens that affects patients with 
thalassemia, as thalassemia leads to low hemoglobin level, fatigue and general 
weakness (Politis, Di Palma et al. 1990, Bush, Mandel et al. 1998, Gharaibeh, 
Amarneh et al. 2009). In our research sample over quarter of thalassemia 
patients had enlarged spleen.  
 Dental caries is common among patient with thalassemia major (Al‐
Wahadni, Taani et al. 2002, Schrier 2002). This level of disease may be 
explained on the basis of chronic nature of thalassemia. The higher caries 
prevalence can be also attributed to the poor oral hygiene, improper dietary 
habits, lack of dental knowledge, and poor motivation of these patients. In the 
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present study, results revealed that about third of thalassemia patients 
infrequently or didn't perform oral hygiene respectively. The vast majority of 
the patients used toothpaste and brush to clean their teeth daily. Therefore, 
parents are more concerned with serious physical problems, paying lesser 
attention to the dental ailments, and only seek dental care when the child is in 
pain. This poor oral hygiene might be changed after giving teaching that 
emphasis to educate patients regarding the effects of thalassemia on teeth 
(Mehdizadeh, Mehdizadeh et al. 2008). 
 Results reveal statistical significant differences observed among three 
groups of thalassemic patients (F ratio= 6.46, p=0.002) regarding serum 
ferritin, this is parallel with study conducted with Tuysuz (Senol, Tiftik et al. 
2016, Tuysuz and Tayfun 2017) who found that the mean serum ferritin levels 
were significantly higher than the normal values and high ferritin level had a 
negative impact on HRQoL. The present study showed that the mean score of 
ferritin of adolescent group was higher than other groups. These findings are 
in agreement with previous study (Beratis 1993) that found rejection of 
treatment by adolescents and young adults is a recognized problem, whereas 
these findings are inconsistent with Safizadeh et al (Safizadeh and 
Farahmandinia 2012) who found no statistical differences in all aspect of 
quality of life with serum ferritin level.    
 In the present study, results revealed that 115 out of 238 (48.3%) of the 
sample used Desferal subcutaneously, while (51.7%) used oral chelation 
(Exjade).      Through revising the 16 steps of administering Desferal S.C that 
were included in the teaching guide for both caregivers and patients, results 
reveal fourteen steps out of sixteen steps were improved by comparing the 
percentage of each before and after distributing the teaching guide. Statistical 
significant differences were found in performing all these steps before and 
after distributing the guide through comparing the overall performance 
(12.52±1.77 compared to 14.07±1.01). (Paired t test = 11.477, p= 0.000). The 
result is supported by a study carried by Abu- Salim who reported that skill 
score of administrating Desferal S.C was improved after a self- care program 
for children with thalassemia (Abu-Salim L 1999). In addition, chelation 
therapy indeed is difficult to accept because it is a daily reminder of one’s own 
illness (Roy and Chatterjee 2007). It is usually performed in the evening when 
patients seek greater reassurance to be able to sleep peacefully. They may 
therefore complain of difficulty getting to sleep and resting well. There is no 
doubt that compliance rate can be improved by health education of both 
thalassemic patients and their caregivers. This fact is supported by numerous 
studies (Tsiantis, Anastasopoulos et al. 1990, Politis 1998, Atkin and Ahmad 
2000, Hoch, Göbel et al. 2000, Angastiniotis 2002) 
 In this study, overall quality of life score ranged from 21.7 to 99.1, with 
a mean score M±SD (62.3±18.0 compared to 67.5±16.4) of adolescent and 
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adult group respectively. These results are comparable to those described by 
(Burckhardt and Anderson 2003, Mann‐Jiles and Morris 2009, Kaheni, 
Yaghobian et al. 2013, Senol, Tiftik et al. 2016) who reported that QoL has 
low to moderate correlation with physical health status. 
 No statistical significant differences were noticed between the two age 
groups regarding 24 items of the quality of life. However, mean scores in 
physical health, psychological, social relationships and environmental 
domains insignificantly better in adult rather than adolescent groups (p>0.05). 
Through comparing the overall quality of life scores between the two age 
groups by taking into account all four domains together, results also reveal no 
statistical significant differences between the adolescent and adult group. This 
might indicate that the adult group adapted relatively well physically and 
psychologically to the burden of chronic illness and treatments. . Findings of 
this study are in agreement with a study conducted by (Amani, Fathi et al. 
2015) who reported that the quality of life among the patients with thalassemia 
in Ardabil was very good, and (Ali, Tarawah et al. 2015) who found in his 
study conducted in KSA that the quality of life in thalassemia patients was 
similar to the control group. Findings of this study are in agreement with  
Kaheni et al (Kaheni, Yaghobian et al. 2013), Gharaibeh et al (Gharaibeh and 
Gharaibeh 2012) and Cheuk et al (Cheuk, Mok et al. 2008) that stated better 
quality of life with the passage of time. On other hand, our findings were 
inconsistent with other studies (Cheuk, Mok et al. 2008, Ansari, Baghersalimi 
et al. 2014) reported that the QOL in all 6 dimensions was lower in patients 
compared to the controls. 
        Furthermore, the findings showed that patient’s age was not associated 
with HRQoL scores. These findings were parallel with (Gharaibeh and 
Gharaibeh 2012, Haghpanah, Nasirabadi et al. 2013, Ali, Tarawah et al. 2015, 
Amani, Fathi et al. 2015) who found there were no significant differences 
between age and quality of life among their study sample. On other hand our 
findings were inconsistent with those reported by Dahlui and colleagues 
(Dahlui, Hishamshah et al. 2009) who found there were significant differences 
in quality of life according to age, quality of life was lowered as age increased 
and with Dhirar et al (Dhirar, Khandekar et al. 2016) who reported that the 
total quality of life scores were better for boys as compared to girls but the 
difference was not statically significant (p= 0.131).  
 No statistical significant differences were found between the two 
treatment groups (subcutaneous vs oral) regarding 24 items of the quality of 
life. However, mean scores for each independent domain were better in 
subcutaneous rather than oral group, but these mean scores were statistically 
insignificant (p>0.05). Through comparing the overall quality of life scores 
between the two groups, results also reveal that no statistical significant 
differences were found between the subcutaneous and oral group respectively, 
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with a mean score M±SD (65.5±17.9 compared to 62.1±16.0).  
 The findings of current study were in agreement with Torcharus et al. 
2011 (Torcharus and Pankaew 2011) , (Kaheni, Yaghobian et al. 2013) , 
Trachtenberg et al (Trachtenberg, Mednick et al. 2012) and (Ali, Tarawah et 
al. 2015) who reported  that is no statistical significant differences were found 
in their studies regarding QOL based on type of iron chelation therapy, and 
these findings are inconsistent with other studies Surapolchai et al 2010 
(Surapolchai, Satayasai et al. 2010) and Tavorncharoensap et al 2010 
(Thavorncharoensap, Torcharus et al. 2010) who found there was statistical 
significant differences in quality of life scores due to iron chelation therapy. 
On the other hand, Dhirar et al (Dhirar, Khandekar et al. 2016), Goulas et al 
(Goulas, Kourakli-Symeonidis et al. 2012) and  Cheuk et al. (Cheuk, Mok et 
al. 2008),  Osborne et al. (Osborne, Lourenço et al. 2007) reported that patients 
on Desferasiox (oral chelation) had significantly better self-related QoL than 
patients on other iron chelation regimen. Other studies also reported that the 
use of Desferal was a strong impediment of QoL, and effective oral chelation 
therapy might improve QoL (Ratip, Skuse et al. 1995, Caro, Ward et al. 2002, 
Kuo, Tsai et al. 2006, Thavorncharoensap, Torcharus et al. 2010, Ansari, 
Baghersalimi et al. 2014, Senol, Tiftik et al. 2016).  
       
Conclusion 
 In this study we assessed the effects of knowledge, attitude and 
practice of thalassemia patients and their caregivers, on the patient's quality of 
life. Our findings highlighted that there was lack and scarcity of patients’ 
knowledge and skills regarding the disease. There has been a remarkable 
improvement in both knowledge and performance after patients received the 
teaching guide. It is recommended to pay more attention in different aspects 
of life of these patients helping to improve their quality of life in all 
dimensions. Furthermore, it is necessary to improve patients’ and their 
families’ awareness regarding this disease. We also found that thalassemia and 
its complications have a negative impact on physical function, education, time 
off school, difference from friends/sibling, social interaction, playing and 
engaging in group activities and stigmatization. In addition, patients with 
thalassemia and their families often require support in many aspects, 
especially psychological support to prevent mental disorders. 
 Moreover, quality of life of patients in the four domains; physical, 
social, psychological and environmental health regarding to the patients’ age 
was above average, also it was above average in physical, psychological and 
environmental domains regarding the patients' gender while it was less than 
average in social domain in females. The findings show there were differences 
between the four domains of quality of life regarding two types of iron 
chelation treatment (subcutaneous and oral), subcutaneous treatment was 
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higher in all domains but the overall quality of life was higher also in 
subcutaneous but not statistically significant.   
 Thalassemia patients have many limitations in their daily life. Proper 
strategies are required for an effective prevention and treatment of this disease. 
Medical staff should focus on disease specific educational programs for 
patients with thalassemia about the entity and the process of the disease, its 
managements, self-care needs, importance of regular iron chelation therapy 
and its role in preventing or delaying complications. By improving these 
methods and giving much more social and psychological support, we could 
improve their quality of life. 
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